MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
Rhea-AI Summary
MiNK Therapeutics (NASDAQ: INKT) will report first quarter 2026 financial results for the period ended March 31, 2026, before market open on May 15, 2026. A conference call and webcast will be held at 8:30 AM ET to review results and provide a corporate update.
The update will cover progress across the iNKT cell therapy platform, including clinical development, translational research, platform expansion, strategic initiatives, continued advancement of lead allo-iNKT therapy agenT-797, recent scientific presentations, and a collaboration with C-Further on a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers. A live webcast and replay will be available on the company website.
AI-generated analysis. Not financial advice.
Positive
- Advancing lead allo-iNKT therapy agenT-797 across cancer and immune disease settings
- Scientific presentations highlighting platform’s potential role in immune activation and reprogramming
- Collaboration with C-Further to develop PRAME-targeted, TCR-engineered iNKT therapy for pediatric cancers
- Platform designed for off-the-shelf, scalable iNKT cell therapies bridging innate and adaptive immunity
Negative
- None.
News Market Reaction – INKT
On the day this news was published, INKT declined 0.82%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
INKT is nearly flat (-0.18%) while peers show mixed moves: ALXO up 10.05%, HOWL up 9.98%, ARTV down 9.38%, PRLD down 5.63%, pointing to stock-specific quiet ahead of earnings timing news.
Previous Earnings date Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Earnings date notice | Positive | +4.9% | Announced FY2025 results date plus iNKT platform expansion and C‑Further collaboration. |
The prior earnings-date announcement in March 2026 coincided with a positive 4.93% move, suggesting investors have previously reacted constructively to similar scheduling updates.
Recent history for MiNK shows steady communication around financial events and platform development. On March 17, 2026, an earnings-date press release with added platform expansion details and a C‑Further collaboration preceded a 4.93% gain. Subsequent releases in late March and April highlighted Q4/FY 2025 results, clinical progress for agenT‑797, and multiple conference presentations. Today’s Q1 2026 earnings-date notice continues this pattern of pairing financial timing with strategic iNKT platform commentary.
Historical Comparison
In the past 6 months, MiNK issued 1 prior earnings-date release, which saw a 4.93% move. Today’s Q1 2026 scheduling plus platform commentary fits that established communication pattern.
Earnings-date releases have evolved from simply scheduling calls to emphasizing platform expansion, including the C‑Further PRAME-targeted TCR‑engineered iNKT collaboration and broader iNKT clinical programs.
Regulatory & Risk Context
MiNK has an effective shelf registration to offer up to $150,000,000 of securities, with an associated ATM program for up to $50,000,000 in common stock and current ATM capacity of $6,641,284 based on a public float of $35,031,699. This structure provides flexibility to raise capital for R&D and corporate purposes, including iNKT platform expansion.
Market Pulse Summary
This announcement sets the timetable for MiNK’s Q1 2026 results on May 15, 2026 and signals a platform-focused update on agenT‑797 and engineered iNKT programs. It follows prior communications about non-dilutive funding and collaborations, including the C‑Further PRAME-targeted TCR‑engineered iNKT effort. Investors may watch for details on cash usage versus the $13.4M year-end 2025 cash and how the existing $150,000,000 shelf and ATM flexibility support ongoing trials.
Key Terms
allogeneic medical
invariant natural killer T (iNKT) cell therapies medical
tcr-engineered medical
prame-targeted medical
AI-generated analysis. Not financial advice.
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the first quarter ended March 31, 2026, before the market opens on Friday, May 15, 2026.
The Company will host a conference call and webcast at 8:30 AM ET that morning to review financial results and provide a corporate update on recent progress across its iNKT cell therapy platform, including clinical development, translational research, platform expansion, and strategic initiatives.
The update will follow several recent corporate and development milestones, including continued advancement of MiNK’s lead allo-iNKT cell therapy, agenT-797, across cancer and immune-mediated disease settings, recent scientific presentations highlighting the platform’s potential role in immune activation and immune reprogramming, and the Company’s collaboration with C-Further to advance a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers.
MiNK continues to advance a differentiated iNKT platform designed to bridge innate and adaptive immunity, support cytotoxic immune responses, and enable off-the-shelf, scalable cell therapy approaches across high-need disease areas.
| Conference Participant Dial Information | |
| United States - New York | (646) 307-1963 |
| USA & Canada - Toll-Free | (800) 715-9871 |
| Conference ID - | 4876136 |
Webcast & Replay Information
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website following the event.
Live event link: https://edge.media-server.com/mmc/p/n4ak2xfn
Webcast Replay: https://investor.minktherapeutics.com/events-and-presentations
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK’s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse.
Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for agenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law.
Contacts
Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com
Source: MiNK Therapeutics
